New ultra-low dose pill 100 percent effective in lowering BP: Lancet

Melbourne : A new ultra-low dose four-in-one pill has been found to be 100 per cent effective at tackling high blood pressure, according to the results of a clinical trial published in The Lancet journal.

Every patient on the pilot trial conducted by The George Institute for Global Health in Australia saw their blood levels drop to normal levels in just four weeks.

Recognising the need to check whether trial results were "too good to be true", the researchers also completed a systematic review of past trials, including 36 trials with 47,500 patients testing single and dual quarter-dose therapy.

This previous evidence also indicated little or no side effects with very low doses, and important benefits with three or four drug combinations.

Professor Clara Chow, of The George Institute, said the results were exciting but larger trials were still needed to see if these high rates could be maintained and repeated.

"Most people receive one medicine at a normal dose but that only controls blood pressure about half the time. In this small trial blood pressure control was achieved for everyone. Trials will now test whether this can be repeated and maintained long-term," Chow said.

"Minimising side effects is important for long-term treatments we didn't see any issues in this trial, as you would hope with very low dose therapy, but this is the area where more long-term research is most needed.

"We know that high blood pressure is a precursor to stroke, diabetes and heart attack. The need for even lower blood pressure levels has been widely accepted in the last few years. So this could be an incredibly important step in helping to reduce the burden of disease globally," said Chow.

Hypertension or high blood pressure affects around 1.1 billion people worldwide.

Over four weeks 18 patients in Sydney were either given a quadpill a single capsule containing four of the most commonly used blood pressure-lowering drugs each at a quarter dose or a placebo.

This was then repeated for a further four weeks with the patients swapping their course of treatment.

Blood pressure levels were measured hourly over a 24 hour period at the end of each treatment, allowing researchers to significantly reduce the amount of patients normally required in a clinical trial.

As many as 100 per cent of patients on trial saw their blood levels drop below 140 over 90. Just 33 per cent of patients on the placebo achieved this rate.

None of the patients experienced side effects commonly associated with hypertension lowering drugs, which can vary from swollen ankles to kidney abnormalities depending on the type of class of the drug.

"What makes these results even more exciting is that these four blood pressure medications are already in use. We are increasingly finding there are opportunities to treat many commons diseases hiding in plain sight. This ultimately means we will be able to deliver life changing medications much more quickly, and more affordably," Chow said.